Free Investing

Gary Gordon submits: In general, I believe that certainty breeds investing success. So even if the long-term ramifications on large-scale health care legislation is poorly understood, the near-term certainty of passage should have produced market-beating gains for Health Care ETFs. Beyond my certainty-uncertainty reasoning, you also have traditional undervaluation in a lot of health care stocks. You have a large number of M&A transactions in biotech. You even have recent historical examples (e.g., Citigroup, AIG, GM, etc.) where following the government’s involvement has benefited investors. Complete Story »

Morningstar submits: By John GabrielThe health-care reform saga rolls on. Those hoping for clarity out of Washington following last week's bipartisan Healthcare Summit were probably disappointed at what essentially amounted to seven hours of nationally televised political theatre.Complete Story »

Joseph Krueger submits: At the 28th annual JP Morgan Healthcare conference, which ran from January 11- January 14th 2010, there were more than 300 companies represented, making their presentations to more than 6000 public and private equity and venture capital investors.Leading up to the conference and early last week there was bullish movement in many companies presenting at the conference. Many of the many of the larger companies like Amgen (AMGN), Genzyme (GENZ), Biogen (BIIB), Celgene (CELG), Gilead Sciences (GILD), TEVA Pharmaceuticals TEVA), Watson Pharmaceuticals (WPI) and OSI Pharmaceuticals (OSIP) previewed 2009 earnings during the conference.Complete Story »

Tom Lydon (ETF Trends) submits: The biotechnology sector and its related ETFs have seen a handsome rebound off the March 9 lows, but does the cash-strapped sector have what it takes to survive for the long haul?Analysts estimate that nearly half of all biotechnology firms have insufficient cash on hand to last them one year. As a result, they’re turning to creative ways to raise cash and alternative exit strategies in order to bring their products to market, states Sumantha Sedor of Genetic Engineering and Biotechnology News.Complete Story »